Seagen and LAVA Therapeutics Ink $700M+ Deal for EGFR Solid Tumor Platform

Bothell-based biotech Seagen is partnering on a licensing deal with LAVA Therapeutics for its solid tumor technology.

LAVA-1223, a preclinical medication that uses LAVA’s patented Gammabody technology to target epidermal growth factor receptor (EGFR)-expressing solid tumors, will be licensed exclusively to Seagen. The transaction could be worth more than $700 million, with Seagen paying up to $650 million in milestone payments.

Lava-1223 can potentially be a first-in-class treatment designed to target and activate gamma delta T-cells in EGFR-expressing tumors. Seagen could negotiate rights to use the Gammabody technology for up to two additional tumor targets.